MedGenome to launch genetic test to diagnose FSHD1
28 February 2023
MedGenome Labs has announced the launch of its Optical Genome Mapping Test (OGM) for diagnosing Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) in India to provide an assessment of the genetic changes in patients with FSHD1. The test can detect large-scale insertions and duplications, as well as more subtle changes in DNA that can cause FSHD1.
MedGenome Labs has announced the launch of its Optical Genome Mapping Test (OGM) for diagnosing Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) in India to provide an assessment of the genetic changes in patients with FSHD1. The test can detect large-scale insertions and duplications, as well as more subtle changes in DNA that can cause FSHD1.
Stay Connected, Stay Informed –
Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.
Pre Ipo
Upcoming IPO
Unicorn
Planify Enterprises Private Limited
Planify Capital Limited
Licensed By
Mutual Fund License No.:
ARN-164419
IRDA Code (1):
ABLIC1003123454
IRDA Code (2):
ABLIC1003131639
Startup India Certificate No.:
DIPP93786
Other Websites
ⓒ 2016-2026 Planify. All rights reserved, Built with
in India
